CAS 1195765-45-7: Dabrafenib
Description:Dabrafenib is a small-molecule inhibitor primarily used in the treatment of certain types of cancer, particularly melanoma with BRAF V600E mutations. It functions by selectively inhibiting the BRAF protein, which is part of the MAPK/ERK signaling pathway, thereby disrupting the proliferation of cancer cells. The substance is characterized by its molecular formula, which includes carbon, hydrogen, nitrogen, and oxygen atoms, and it has a specific molecular weight. Dabrafenib is typically administered orally and is known for its relatively high bioavailability. Its pharmacokinetics indicate a moderate half-life, allowing for once or twice daily dosing. Common side effects may include fever, fatigue, and skin-related reactions, reflecting its impact on both cancerous and normal cells. Additionally, it is often used in combination with other therapies, such as trametinib, to enhance its efficacy. As with many targeted therapies, monitoring for resistance mutations is crucial for maintaining treatment effectiveness.
Formula:C23H20F3N5O2S2
InChI:InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
InChI key:InChIKey=BFSMGDJOXZAERB-UHFFFAOYSA-N
SMILES:O=S(=O)(NC=1C=CC=C(C1F)C=2N=C(SC2C=3N=C(N=CC3)N)C(C)(C)C)C=4C(F)=CC=CC4F
- Synonyms:
- Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-
- Dabarefenib
- Dabrafenib
- Debrafenib free base
- Gsk 2118436
- Gsk 436
- N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
- N-[3-[5-(2-Aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
- Tafinlar
- Tafmlar
- See more synonyms
